If you cannot access ON24, please view the recording here.
Join us for an upcoming webinar on the PACE Trial, where we will delve into the latest findings and insights on this groundbreaking study. Led by Professor van As, this multi-center, randomized controlled trial has already shown promising results and has the potential to change the landscape of prostate cancer treatment.
During the webinar, we will hear results from both PACE-A and PACE-B trials and discuss the implications of these findings for patients and healthcare providers alike.
Presenter: Nicholas van As, MBBCh, MRCP, FRCR, M.D.(res), The Royal Marsden and Institute of Cancer Research, London, UK
Prof. Nicholas van As is the Royal Marsden Hospital Medical Director, Consultant Clinical Oncologist in the Urology Unit, and a Professor at the Institute of Cancer Research, London, UK.
Prof. van As is a clinical lead for stereotactic body radiotherapy (SBRT) at The Royal Marsden and national clinical lead for NHS England’s evaluation program for SBRT. He is Chair of the UK SBRT Consortium. He leads a number of clinical trials. Most notably, he is the chief investigator for the international clinical trial PACE, comparing SBRT to image-guided radiotherapy and surgery for treating localized prostate cancer.
Prof. van As’ primary research interests are in stereotactic and image-guided radiotherapy, treatment of oligometastatic disease, risk prediction in early prostate cancer, and functional magnetic resonance imaging. He has published numerous papers on these subjects and delivered presentations at international meetings.
Moderator: Suneil Jain, MBBCh, MRCP, FRCR, Ph.D., Queen’s University Belfast, Northern Ireland, UK
Suneil Jain is a Professor of Clinical Oncology at Queens University Belfast and an Honorary Consultant Clinical Oncologist at the Northern Ireland Cancer Centre, Belfast.
He is an expert in advanced radiotherapy and systemic therapies for prostate cancer. Prof Jain leads multiple clinical trials in Northern Ireland; his research interests include radiomic and genomic biomarkers to improve risk stratification in prostate cancer, the utilisation of nanotechnology to enhance the effects of radiation therapy, stereotactic radiotherapy and brachytherapy in high-risk prostate cancer and drug-radiotherapy combination studies in early metastatic disease. He is the Chief Investigator on the SABRE phase III clinical trial evaluating SpaceOAR Vue in patients treated with stereotactic radiotherapy and the Clinical Lead for the PACE NODEs phase III clinical trial. He is Co-Director of the Belfast-Manchester Movember/PCUK Prostate Cancer Centre of Excellence, Co-Director of the Prostate Cancer Centre of Research Excellence at QUB, a member of the RCR radiotherapy board and past-Chair of the Irish Radiation Research Society.
